A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering mechanism of action for the treatment of Alzheimer’s disease. Unlike current drugs, which mainly remove beta-amyloid plaques that accumulate in the brain, this new experimental drug reprogrammes the neuronal epigenome by correcting alterations in gene expression that contribute to the progression of the disease. The results of this study, published in Molecular Therapy, open the door to an epigenetic-based therapeutic strategy to fight Alzheimer’s disease.

This review examines the gut–brain axis (GBA) as a critical bidirectional network linking gut microbiota to brain function and pathology. It details key pathways—neural, immune, endocrine, and metabolic—through which gut-derived signals influence conditions like depression, Alzheimer’s, and Parkinson’s disease. The article highlights novel microbiota-targeted therapies, including probiotics, fecal transplantation, and dietary strategies, underscoring their potential for pioneering personalized approaches in neuropsychiatry. These hold promises for innovative treatments. Personalized medicine is the way forward.

Longitudinal follow-up reveals that a significant proportion of these lesions may stabilize or even decrease once Alzheimer’s disease symptoms are present, challenging the concept of exclusively cumulative vascular damage.

Published in Alzheimer’s & Dementia, one of the leading international journals in dementia research, the study provides new data on the interaction between vascular alterations, neurodegeneration, and beta-amyloid and tau proteins in the brain.

The findings reinforce the need to analyze Alzheimer’s disease from a temporal perspective, as the evolution of these lesions cannot be explained solely by the progression of classical biomarkers.

Evan Dewey makes friends everywhere he goes. He’s buddies with the Vonlane bus drivers who transport him and his father, Brian, from his hometown of Atlanta to the Vanderbilt Center for Cognitive Medicine — the closest enrollment site for the worldwide ABATE study that is testing a potential treatment for Alzheimer’s disease in people with Down syndrome.

New UC Riverside-led research suggests Alzheimer’s arises not simply from plaques forming in the brain, as is widely believed, but from one protein interfering with the normal job of another.